Navigation Links
FDA Approves First Hepatitis B Viral Load Test
Date:9/4/2008

Another Roche first in TaqMan(R) real-time PCR testing for the diagnostic

lab

PLEASANTON, Calif., Sept. 4 /PRNewswire/ -- The U.S. Food & Drug Administration (FDA) has approved the Roche COBAS(R) TaqMan(R) HBV Test, the first assay for quantitating Hepatitis B Virus DNA approved in the U.S. The test uses Roche's real-time PCR technology to quantify the amount of Hepatitis B virus DNA in a patient's blood. Doctors may use viral load testing results to establish a baseline level of infection and during treatment as an aid in assessing individual responses to therapy. Widespread application of antiviral therapy along with the Hepatitis B vaccine has helped reduce prevalence; however, Hepatitis B remains a serious and potentially life threatening global disease, potentially resulting in death from extensive liver damage or liver cancer for chronically infected people.(1)

"Viral load testing with an FDA approved test has long been the standard for managing patients with HIV and Hepatitis C," said Teresa Wright, M.D., Chief Medical Officer at Roche Molecular Diagnostics. "Availability of this new Roche test enables doctors and laboratories to bring that same level of standardized viral load measurement to Hepatitis B treatment."

Because the goal of Hepatitis B therapy is to treat until the virus is undetectable in the patient's blood, it is critical for viral load monitoring tests to be able to quantify very low levels of virus. Similarly, it is important for the test to quantify very high levels of virus (higher than 100 million IU/mL), an indicator of the need for more or less aggressive treatment. The Roche COBAS(R) TaqMan(R) HBV Test can detect the World Health Organization (WHO) HBV International Standard in plasma and serum as low as 3.5 IU/mL and 3.4 IU/mL respectively. The test can measure HBV DNA as high as 1.10E8 IU/mL, representing a significantly broader dynamic range than previously available test
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
3. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
4. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
5. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
6. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
7. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
8. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
9. U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
10. FDA Approves HIFU Clinical Trial for Recurrent Prostate Cancer
11. EPA Approves XDS-CALUX(R) as Alternate Dioxin Test Method 4435
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 Neurelis, Inc. ("Neurelis") today ... end the option held by Biotie to purchase Neurelis, ... of NRL-1 (intranasal diazepam) for pediatric and adult epilepsy ... the past year, Biotie has advanced the development program ... the pivotal clinical work required for NDA submission to ...
(Date:7/10/2014)... 2014  The U.S. Department of Health and Human ... Hospitals (UH) Case Medical Center Seidman Cancer Center totaling ... at improving care for patients with complex cancer. ... test a unique model developed at UH to enhance ... comorbidities, or demonstrated need for high health care utilization.  ...
(Date:7/10/2014)... INC. (NYSE: RMD ) today announced that it ... 30, 2014 results on Thursday, July 31, 2014, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
Breaking Medicine Technology:Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2
... Clinical Program Leverages Quark,s RNAi Technology, FREMONT, ... pharmaceutical company discovering and developing novel,RNA interference (RNAi)-based ... patient dosing in a Phase II trial,evaluating, ... (DME)., PF-4523655 is a novel siRNA drug ...
... Does Not Mean the End of Anti-Amyloid,Therapies -, ... studies,of potential new treatments for Alzheimer,s - even ... field,s knowledge and point scientists,toward advances in therapies ... the 2008 Alzheimer,s Association International Conference,on Alzheimer,s Disease ...
Cached Medicine Technology:Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 2Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 3Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 2Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 3Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 4Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 5Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 6Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 7Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 8Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 9Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 10Four Alzheimer's Clinical Trials Address a Variety of Treatment Targets - Amyloid, Tau, Synapse Formation 11
(Date:7/12/2014)... prom shopping reaching its final days, VogueQueen.com, a renowned ... its new and trendy apparels. Recently, the company has ... online shop. Additionally, it is now providing huge discounts ... to the company’s sales manager, the promotion will come ... He says, “Now, worldwide clients can order cheap ...
(Date:7/12/2014)... PA (PRWEB) July 12, 2014 Doylestown ... covering a variety of men’s health questions. Paddock ... specific to men, why women live longer than men, ... Men's Health Made Simple featured on Doylestown ... get a hernia at any age. If you notice ...
(Date:7/12/2014)... (PRWEB) July 12, 2014 A recent article ... provides a trio of suggestions for those seeking cosmetic ... days are rapidly approaching and the heat begins to enliven ... to their summer clothing, realizing that they didn’t work out ... , This can cause a sudden surge of people eager ...
(Date:7/12/2014)... July 12, 2014 Floor-grade ... of 4.1 out of 5. This above-average score ... been underpinning buyer negotiation power over the three ... Anna Son, “during the period, surging demand for ... associated with new product development, have placed upward ...
(Date:7/11/2014)... MagicQuinceaneraDresses.com, the popular online supplier of special occasion gowns, ... dresses . The company’s new items are specially designed ... a large amount of money. They are all available ... company’s online shop has become a one stop platform ... addition to exquisite Quinceanera dresses, it also offers great ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com Updates Its Summer Collection With New And Trendy Evening Dresses 2Health News:Ivyland Medical Center’s Dr. Brad Paddock Offers Tips for Men’s Health 2Health News:Best Summer Cosmetic Surgeries Revealed in Article By Seattle Plastic Surgeon 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Floor-Grade Instruments Procurement Category Market Research Report from IBISWorld has Been Updated 4Health News:Cheap Quinceanera Dresses Now Available At MagicQuinceaneraDresses.com 2
... sexual intercourse for couples lasts from 3 to 13 ... hours of sexual activity, according to a survey of ... Eric Corty and Jenay Guardiani conducted a survey of ... and Research, which include psychologists, physicians, social workers, marriage/family ...
... Will Arnett, Matthew Broderick, Steve Carell, Stephen, Colbert, ... James,Conan O,Brien, Rosie O,Donnell, Amy Poehler, Adam Sandler, Sarah ... Insult Comic Dog And Many More To Be Announced, ... today that,Kelsey Grammer, Ben Stiller, Grammy Award-winning band Maroon ...
... Work in primates points to possible weapon against human ... News) -- Researchers have successfully tested several Ebola vaccines ... first human vaccine for one of the world,s deadliest ... cannot be overlooked. We are seeing more and more ...
... French . , Montreal, March 31, 2008 ... novel gene responsible for a significant fraction of ALS (sporadic ... Lou Gehrigs disease, an incurable neuromuscular disorder that affects motor ... five years. , Published in the current online edition of ...
... March 31 The Epilepsy,Foundation,s quick reaction to a ... raises awareness of the need for Web security for ... and those who,use its online forums for help, support, ... posted rapidly flashing images to cause,serious injury and harm. ...
... --- University of Florida chemists are the first to use ... diseases -- without any previous knowledge of what these microscopic ... in the online edition of the Journal of Proteome Research, ... improved treatment of some types of cancer as well as ...
Cached Medicine News:Health News:Good sexual intercourse lasts minutes, not hours, therapists say 2Health News:Kelsey Grammer, Ben Stiller, Maroon 5 and The Roots Added to COMEDY CENTRAL's(R) Live On-air Charity Special 'Night of Too Many Stars: An Overbooked Concert for Autism Education' Hosted by Jon Stewart on Sunday April 13, at 8 p.m. ET 2Health News:Researchers Successfully Test Ebola Vaccines 2Health News:Researchers identify a gene responsible for cases of Lou Gehrig's disease 2Health News:Epilepsy Foundation Takes Action Against Hackers 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 2Health News:Scientists: New technique identifies molecular 'biomarkers' for disease 3